Secretary Kennedy seeks to enhance FDA's oversight of food additives by eliminating a pathway that allows new ingredients to be introduced into ...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...

The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

The Food and Drug Administration March 20 issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems.

The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

The approval is only for the 2.5mg tablet. The Food and Drug Administration (FDA) has approved the first generics of Xarelto ® (rivaroxaban) 2.5mg. Xarelto 2.5mg is used, in combination with ...

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular ...